Back to Search
RICHARD RATNER, M.D.
M.D.
Forensic Psychiatry Physician
NPI: 1023074747Individual
Specialties, Licenses & Credentials
Forensic Psychiatry PhysicianPrimary
Psychiatry & Neurology — Forensic Psychiatry
Code: 2084F0202X
MD5492(DC)D0014682(MD)
Research & Publications (20)
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
PMID 19033001·Am Heart J·2008
4-observational
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
PMID 15793191·Diabetes Care·2005
3-trial
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
PMID 15891954·Exp Clin Endocrinol Diabetes·2005
3-trial
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
PMID 15498087·Diabet Med·2004
3-trial
Ethics in child and adolescent forensic psychiatry.
PMID 12397904·Child Adolesc Psychiatr Clin N Am·2002
8-other
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
PMID 12017421·Diabetes Technol Ther·2002
3-trial
Glycemic control in the prevention of diabetic complications.
PMID 11838325·Clin Cornerstone·2001
6-review
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
PMID 10834423·Diabetes Care·2000
3-trial
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.
PMID 19366774·JAMA·2009
2-rct
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
PMID 19366970·Diabetes Care·2009
3-trial
Risk factors associated with methamphetamine use and heart failure among native Hawaiians and other Pacific Island peoples.
PMID 19436660·Vasc Health Risk Manag·2009
2-rct
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
PMID 18819705·Lancet·2009
3-trial
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
PMID 19358783·J Clin Psychiatry·2009
4-observational
Actos Now for the prevention of diabetes (ACT NOW) study.
PMID 19640291·BMC Endocr Disord·2009
8-other
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
PMID 19171717·Diabetes Care·2009
2-rct
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
PMID 19626663·Diabetes Metab Res Rev·2009
4-observational
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
PMID 18826999·J Clin Endocrinol Metab·2008
2-rct
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
PMID 19095139·J Am Coll Cardiol·2008
3-trial
[Nutritional status and lifestyles of workers from two regions in Chile].
PMID 19301771·Rev Med Chil·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5028 WISCONSIN AVE NW, SUITE 303
WASHINGTON, DC 20016 - Phone
- (202) 686-2200
Quick Facts
- NPI
- 1023074747
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile